Atara Biotherapeutics, Inc. ATRA
Atara Biotherapeutics is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune disease. Tab-cel®(tabelecleucel), has received marketing authorization approval under the proprietary name Ebvallo by the European Commission (EC) for commercial sale and use in the European Economic Area (EEA), by the Medicines and Healthcare products Regulatory Agency (MHRA) for commercial sale and use in the United Kingdom (UK) and by Swissmedic for commercial sale and use in Switzerland. We partnered with Pierre Fabre Medicament (Pierre Fabre) for commercialization of tab-cel in Europe and potential commercialization, if approved, worldwide, including in the U.S. Tab-cel is currently in Phase 3 development in the U.S. for patients with EBV- associated post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M | — | — | — | — | — | — |
| R&D | $37.4M | $151.5M | $224.8M | $272.5M | $282.0M | $244.7M | $216.1M | $167.5M | $81.2M | $56.5M |
| SG&A | $26.3M | $39.9M | $50.9M | $71.6M | $78.8M | $64.4M | $79.6M | $69.7M | $40.3M | $24.7M |
| Total operating expenses | $84.9M | $212.4M | $284.6M | $344.1M | $360.8M | $309.1M | $295.7M | $237.1M | $121.5M | $81.2M |
| Operating income | $35.9M | -$83.4M | -$276.0M | -$280.5M | -$340.5M | -$309.1M | -$295.7M | -$237.1M | -$121.5M | -$81.2M |
| Interest expense | $3.8M | $4.6M | $5.3M | $373.0K | — | — | — | — | — | — |
| Pre-tax income | $32.7M | -$85.4M | -$276.1M | -$228.3M | -$340.1M | -$306.6M | -$291.0M | -$230.7M | -$119.5M | -$79.0M |
| Income tax | $31.0K | $12.0K | $15.0K | $12.0K | $46.0K | $15.0K | $12.0K | $44.0K | $14.0K | $10.0K |
| Net income | $32.7M | -$85.4M | -$276.1M | -$228.3M | -$340.1M | -$306.6M | -$291.0M | -$230.7M | -$119.5M | -$79.0M |
| EPS, basic | 2.61 | -11.41 | -65.19 | -2.24 | -3.63 | -4.15 | — | — | — | — |
| EPS, diluted | 2.57 | -11.41 | -65.19 | -2.24 | -3.63 | -4.15 | -5.67 | -5.27 | -4.00 | -2.75 |
| Shares, diluted (wtd. avg.) | $12.7M | $7.5M | $4.2M | $102.0M | $93.7M | $74.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.5M | $25.0M | $26.0M | $93.1M | $107.5M | $201.8M | $75.7M | $62.1M | $80.6M | $48.2M |
| Short-term investments | $0 | $17.5M | $25.9M | $149.9M | $265.0M | $300.3M | $184.8M | $248.9M | $86.9M | $207.7M |
| Receivables | $1.3M | $1.5M | $34.1M | $40.2M | $986.0K | $1.2M | $0 | — | — | — |
| Inventory | $0 | $10.7M | $9.7M | $1.6M | $0 | — | — | — | — | — |
| Total current assets | $12.2M | $64.9M | $101.9M | $295.1M | $384.6M | $523.3M | $273.0M | $321.5M | $172.2M | $260.6M |
| Property, plant and equipment | $73.0K | $1.3M | $3.9M | $6.3M | $53.8M | $50.5M | $54.2M | $68.6M | $44.1M | $3.3M |
| Total assets | $20.2M | $109.1M | $165.5M | $376.4M | $468.1M | $588.1M | $342.9M | $391.8M | $217.8M | $263.9M |
| Accounts payable | $127.0K | $4.4M | $3.7M | $6.9M | $17.4M | $7.1M | $8.0M | $3.7M | $14.7M | $2.8M |
| Total current liabilities | $14.9M | $134.6M | $142.2M | $78.9M | $105.8M | $82.9M | $36.7M | $40.0M | $27.6M | $9.7M |
| Total liabilities | $58.7M | $206.4M | $264.7M | $249.8M | $188.5M | $125.8M | $52.2M | $53.0M | $39.9M | $10.2M |
| Retained earnings | -$2.02B | -$2.05B | -$1.97B | -$1.69B | -$1.46B | -$1.12B | -$818.0M | -$527.3M | -$296.6M | -$177.2M |
| Total equity | -$38.5M | -$97.3M | $99.2M | $126.6M | $279.6M | $462.3M | $290.8M | $339.2M | $177.9M | $253.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$50.9M | -$68.7M | -$193.0M | -$270.4M | -$220.5M | -$180.8M | -$235.6M | -$179.8M | -$87.5M | -$60.0M |
| Depreciation and amortisation | $400.0K | $2.7M | $3.7M | $4.7M | — | — | — | — | — | $383.0K |
| Stock-based compensation | $9.8M | $27.0M | $45.4M | $53.8M | $53.9M | $51.4M | $51.7M | $33.8M | $23.1M | $16.8M |
| Capital expenditure | $0 | $246.0K | $1.2M | $4.2M | $10.6M | $4.5M | $5.7M | $35.9M | $20.2M | $3.0M |
| Investing cash flow | $18.1M | $8.6M | $123.9M | $203.0M | $22.3M | -$120.7M | $60.5M | -$196.3M | $99.9M | $83.7M |
| Financing cash flow | $16.1M | $59.3M | $2.0M | $53.1M | $103.9M | $427.6M | $188.8M | $357.5M | $20.0M | $506.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-177285.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |